drugset / Trial / NCT01301963
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
Phase 3
Terminated
9 enrolled
Case Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide. Giving colony-stimulating factors, such as G-CSF, and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored
Timeline
- Start
- 2011-07
- Primary completion
- 2013-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | — | Subcutaneous |
| Subject | filgrastim | Protein / enzyme biologic | — | Subcutaneous |